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A B S T R A C T
Cyclin-dependent kinase 8 (CDK8) plays a vital role in regulating cell transcription either through its association
with the mediator complex or by the phosphorylation of transcription factors. CDK8-mediated activation of
oncogenes has proved to be important in a variety of cancer types including hematological malignancies. We
have designed and synthesized a series of new synthetic steroids. The compounds were evaluated as CDK8
inhibitors in vitro. The three most potent compounds exhibit Kd-values towards CDK8 in the low nanomolar
range (3.5–18 nM). Furthermore, the compounds displayed selectivity for CDK8 in a panel of 465 different
kinases. The cell studies indicated a selectivity to kill AML-cancer cell lines compared to normal cell lines.
1. Introduction
Cyclin-dependent kinases (CDKs) are a family of serine/threonine
protein kinases that control critical regulatory events during cell cycle
and transcription.1 Given these fundamental roles, it is unsurprising
that deregulation of CDKs is a common feature of many cancers. In
particular, Cyclin-dependent kinase 8 (CDK8), a ubiquitously ex-
pressed, primarily transcriptional member of the CDK family, has come
under focus owing to investigations of its central roles in transcription
and oncogenesis.2–4 Several genetic and biochemical studies have es-
tablished CDK8 as a key oncogenic driver in a variety of different cancer
forms like colon cancer5, prostate cancer6 and melanoma7. It is also
reported that a striking correlation exists between the expression of
CDK8 and the duration of relapse-free survival in patients with breast-
and ovarian cancer8. For example, breast cancer patients with below-
median expression of CDK8 survive without the disease approximately
seven years longer than patients with an above-median expression of
CDK8.9 From a biochemical perspective, CDK8 plays an important role
in regulating transcription either through its association with the
mediator complex or by phosphorylating transcription factors. Specifi-
cally, CDK8-mediated activation of oncogenic Wnt-β-catenin signaling,
transcription of estrogen-inducible genes and suppression of super en-
hancer-associated genes contribute to oncogenesis in colorectal-,
mammary- and hematological malignancies, respectively. Inhibitors of
CDK8 have also been shown to be active in AML cells that have high
activation of the signal transducer and activator of transcription 5
(STAT5).10 STAT5 mediates several malignant properties in AML cells.
Inhibition of STAT5 phosphorylation, through inhibition of for instance
Flt3 or PIM-kinases, has shown therapeutic value.11,12 Another aspect
with CDK8 in cancer is that it is involved in tumor surveillance of NK-
cells. Inhibition of CDK8 is known to increase NK cell cytotoxicity to-
wards cancer cells.13,14 The use of CDK8 inhibitors can therefore have a
double action: First, by acting directly on the cancer cells, and secondly
indirectly by activation the NK cells to more efficiently lyse the cancer
cells. Hence, an interest to develop compounds inhibiting CDK8 has
increased. As of today, based on high throughput screening (HTS) and
computational methods towards different kinase panels, a few com-
pounds have appeared as either CDK8 ligands or inhibitors.15–18
(Fig. 1).
In 2012, the senexin compounds, exemplified by Senexin A (1)
Fig. 1, were revealed as a class of selective CDK8 inhibitors. This group
of compounds was discovered using HTS with more than 100,000
compounds for the downstream inhibition of p21-activation transcrip-
tion. An optimization of the compounds led to Senexin A that was
characterized as a kinase inhibitor with Kd = 0.83 µM and
Kd = 0.31 µM for CDK8 and its structural homolog CDK19, respec-
tively. The kinase activity of CDK8 was inhibited with an
IC50 = 0.28 µM. Cortistatin A (2) is a naturally occurring steroidal
alkaloid isolated from the marine sponge Corticum simplex.19 It was
reported in 2009 that 2 is a high-affinity binder, with Kd = 17 nM,
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towards CDK8.20 In addition to its strong binding affinity, the com-
pound showed a high level of selectivity for CDK8. Cortistatin A was
tested at 10 µM in a high-throughput binding assay against a panel 359
non-mutant kinases, and the calculated selectivity score at 35% control
activity S(35)21, proved to be 0,045. The authors suggested in a binding
model that hydrogen bonding between the nitrogen on the isoquinoline
side chain to Ala100 in CDK8 was important.20 More recently, struc-
tural and mechanistic studies have revealed that compound 2 is a
highly potent, ATP-competitive, CDK8 inhibitor, and utilizes its iso-
quinoline moiety to bind to the kinase hinge segment through the ni-
trogen of the isoquinoline and the NeH of Ala100. The steroidal-like
core makes extensive contacts with the ATP-binding cavity.22 Further-
more, the study investigated the potential of cortistatin A (2) as a
treatment for acute myeloid leukemia (AML) and a 71% tumor growth
inhibition on day 33, in mice containing SET-2 AML xenograft tumors,
was reported. Importantly, cortistatin A had an acceptable pharmaco-
kinetic profile in mice for once-daily intraperitoneal dosing and the re-
duction in the progression of the disease was reported to be dose-de-
pendent.
The heterocyclic compound CCT251921 (3) was originally identi-
fied as a potent inhibitor of the Wnt signaling pathway.23 A follow-up
study using a chemical proteomics-based approach identified CDK8/
CDK19 as its primary targets.24 The compound was claimed to be se-
lective for CDK8/CDK19 in a panel of 279 kinases at 1.0 µM; however
CDK8 itself was not included in the panel as a positive control. Pre-
clinical testing of these compounds showed that the compound in-
hibited Wnt-dependent activity in a number of colorectal cell lines, as
well as the phosphorylation of the transcription factor Signal transducer
and activator of transcription 1 (STAT1) at Ser727. The binding mode
of CCT251921 (3) to CDK8 revealed that its pyridine nitrogen inter-
acted with the kinase hinge segment by a similar interaction to the NeH
of Ala100 as that of the isoquinoline nitrogen of cortistatin A (2). From
this interaction, the indazole substituent of 3 is orientated towards the
ATP-binding cavity in similarity to the steroidal core of cortistatin A.
Additionally, the chlorine-atom, attached to the pyridine ring, in a
meta-relationship to both the nitrogen atom and the indazole, further
increased the affinity of compound 3 by an interaction with Phe97. In
connection with our interest and earlier efforts in using steroids as lead
compounds for the development of new anti-cancer agents,25–30 we
present our experimental approach by taking advantage of this in-
formation in the design of easily accessible steroid-based inhibitors of
CDK8.
2. Results and discussion
2.1. Chemistry – Design and synthesis
In March 2018, Hatcher and coworkers demonstrated that several
steroidal cortistatin A (2) analogs were effective inhibitors of CDK8.31
In this work, we aim to advance their approach further by combining
information of the binding modes of the pyridine core of CCT251921
(3) and the isoquinoline of cortistatin A (2). Compared to the work
published by Hatcher and coworkers, we have included several more
isoquinolinyl-, as well as pyridinyl and indolyl substituents attached to
the unsaturated carbon 17 at the steroidal core. Encouraged by the
work of Baran and coworkers and to simplify the SAR-studies,32 we
choose not to reduce the double bond on the D-ring of the analogs.
Furthermore, the orientation of dimethylamino group of Cortistatin A is
maintained in our analogs at the carbon number of the steroid nucleus.
By this approach, several analogs have been made (see Scheme 1).
The synthesis of compounds 8–17 commenced with a Mitsunobu-
type inversion of the chiral center at C-3 of epiandrosterone (4) to the
corresponding androsterone-3-azide 5 using triphenylphosphine, dii-
sopropyl azodicarboxylate (DIAD) and diphenylphosphorylazide
(DPPA) in THF, from which androsterone-3-azide 5 was isolated in 73%
yield. Then, in a one-pot sequence, a modified Staudinger reaction
using trimethylphosphine in THF was employed to afford the inter-
mediate steroidal amine, which was further converted to the dimethyl
amine 6, by an Eschweiler-Clarke type reaction33–35 The enol-triflate 7
was made from the ketone 6 in a reaction using N-phenyl-bis(tri-
fluoromethanesulfonimide) in the presence of NaHMDS at −78 °C. The
key intermediate 7 was further converted to the desired compounds
8–17 using the Suzuki-Miyaura cross-coupling reaction with different
boronic acids as coupling partners. Tetrakis(triphenylphosphine)palla-
dium and caesium carbonate in THF/H2O (1:1) enabled the preparation
of compounds 8–17 in 31–42% overall yield (see Fig 2).
2.2. CDK8 profiling
Compounds 8–17 were tested for their ability to inhibit probe
binding to protein kinase CDK8 in vitro at 50 nM concentration. In this
assay, the ability of a test compound to compete with an immobilized,
active site directed ligand is quantitatively measured and reported as
percent of DMSO control (POC), with lower numbers indicating higher
binding affinity. The results are displayed in Table 1. Except for 16, all
compounds displayed inhibitory activity towards CDK8 at 50 nM con-
centration. For the five most promising compounds, their Kd-values
were determined. The most potent compound, the 5-isoquinoline
analog 12, inhibited CDK8 with a Kd = 3.5 nM, which is 3–4 times
lower than the reported Kd-value of our lead compound cortistatin A (2)
(17 nM) in a similar assay.20 Compound 12 has a 5-isoquinoline sub-
stituent in the 17-position of the steroid core skeleton. For compound 9,
with a 5-chloropyridin-3-yl substituent as in CCT251921 (3), the Kd-
value was determined to 13 nM in the same range as for cortistatin A
(2).
To evaluate the kinase selectivity, we performed a KinomeScan™
binding analysis against a near comprehensive panel of 468 kinases at a
concentration of 50 nM (Fig. 3). This profiling revealed selectivity of
compounds 12 and 9 for CDK8, both with selectivity scores, S(10) at
0.01.21 Furthermore, compound 14 displayed a Kd = 18 nM and a S(10)
 
Fig. 1. Example of reported CDK8 inhibitors.
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score of 0.01. These results are in line with the data presented by
Hatcher and coworkers in their report from 2018, in which they mea-
sured the IC50 values of 18–24 nM and S(10) score of around 0.01 for a
related compounds carrying isoquinolin-7-yl substituents on the steroid
skeleton.31
2.3. In vitro studies
In order to assess whether the analogs could be lead compounds in
acute myeloid leukemia (AML) therapy, we tested them against three
cell lines derived from AML patients. These were cells with different
mutation status and cytogenetics. The MOLM-13 and MV4-11 cells are
from the monocytic lineage, and display heterozygotic and homo-
zygotic internal tandem duplication (ITD) of Flt3, respectively, which
both are associated with high risk. The OCI-AML3 cell line has wild-
type Flt3, associated with low risk, but a complex karyotype, which
turns this cell line into a high-risk model. In line with this, we have
found that the OCI-AML3 are more resistant than MOLM-13 and MV4-
11 cells to other kinase inhibitors, which did not correspond to ex-
pression of drug transporters.36,37
The CDK8 inhibitors tested had EC50 values between 2.7 µM and
10 µM for the AML cells (Table 1). The analog 13 was the most potent,
with values below 4.1 µM for all AML cell lines (Table 1). Interestingly,
the analogs did not show significantly different activity towards the
three AML cell lines. This suggests that their cell death targets are
different from other cytostatics like daunorubicin and kinase inhibitors,
which for instance have low activity towards the cytogenetically com-
plex OCI-AML3 cells compared to their activity towards MOLM-13 and
MV4-11. The analogs were next tested against the two non-malignant
cell lines NRK (rat epithelial kidney cells) and H9c2 (cardio myoblasts)
to find if the compounds also could affect normal tissue. In comparison
to the malignant cell lines, these cells tolerated two to four times higher
concentration of most of the analogs (Table 2).
3. Conclusion
Herein, ten new synthetic compounds have been reported and
evaluated for their inhibitory properties towards CDK8. The initial
screening of the compounds proved inhibitory effects toward CDK8 at a
concentration of 50 nM. For the five most potent compounds, the in-
dividual Kd-values toward the same enzyme were determined, which
further proved the ability of the compounds to bind to the kinase in
vitro. The Kd-values of the three most potent compounds are in line or
even lower compared to the previous reported CDK8 inhibitors.9,10,20,24
Additionally, when tested towards a panel of 468 different kinases, the
compounds within this study demonstrated a high degree of selective
inhibition of CDK8. Compound 14 is a similar analog to what has al-
ready been reported by Hatcher and coworkers.31 By further structure
activity relationship studies, we have improved both the affinity and
selectivity towards CDK8 for this class of compounds.
Interestingly, the cellular studies identified compound 13 to be the
most cytotoxic compound. This observation is in line with the ob-
servation done by Corey and coworkers, where several isoquinoline
steroidal analogs where tested for their antiangiogenic activity.38
However, low selectivity of this compound towards the AML cell lines,
compared to the non-malignant cell lines, were observed (Table 2). For
the most potent CDK8 inhibitor, compound 12, the EC50 values were
slightly higher, i.e. it was less cytotoxic towards the AML cell lines
(Fig. 3). However, compound 12 proved more selective in killing AML
cell lines, compared to compound 13. The EC50 values are three to four
times lower for compound 12 towards the AML cell lines compared to
the non-malignant cell lines.
Scheme 1. Synthesis of compounds 8–17. Reagents and conditions: i) PPh3, DIAD, diphenyl phosphoryl azide, THF, rt, 10 h, 73%; ii) P(CH3)3, 1 M NaOH, THF, rt.,
2 h; iii) AcOH, CH2O, NaCNBH3, MeOH, rt. 1 h, 73%; iv) NaHMDS, PhN(SO2CF3)2, THF, −78 °C, 4 h, 85%; v) ArB(OH)2, Cs2CO3, Pd(Ph3P)4, THF:H2O (1:1) 60 °C,
5 h, 64–85%.
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4. Experimental
4.1. General methods – Chemistry
All reagents and solvents were used as purchased without further
purification unless stated otherwise. Melting points are uncorrected.
Analytical TLC was performed using silica gel 60 F254 aluminum plates
(Merck). Flash column chromatography was performed on silica gel 60






















































Fig. 2. Tree spot interaction map for compounds 9, 12 and 14 tested at 50 nM concentrations of inhibitors against 468 wild type and mutant human protein and lipid
kinases (KINOMEscan, Eurofins). Kinases where probe binding was inhibited by>80% at 50 nM test compound concentration are listed.
Table 1
Results from in vitro CDK8-evaluation of compounds 8–17.
Compound CDK8 per cent of control
(POC)
Kd (nM) Selectivity score (S10)
8 18% 41 n.d.
9 0% 13 0.02
10 49% n.d. n.d.
11 4.3% n.d. n.d.
12 0% 3.5 0.14
13 7.3% 45 n.d.
14 0% 18 0.07
15 68% n.d. n.d.
16 100% n.d. n.d.
17 83% n.d. n.d.
Fig. 3. The cytotoxic effect of compound 12 on the AML cell lines MOLM-13,
OCI-AML and MV4-11 as well as the non-cancerous NRK cell line. The cells
were exposed to various doses of 12 for 48 h and the metabolic activity of the
cells was assessed by the WST-1 assay. The data are average of two–four ex-
periments and standard error. The lines are from four-parameter regression
analyses. For experimental details see the experimental section.
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(40e63 mm) produced by Merck. NMR spectra were recorded on a
Bruker Avance DPX-300 MHz, DPX-400 MHz or DPX-600 MHz spec-
trometer for 1H NMR, and 75 MHz, 101 MHz or 151 MHz for 13C NMR.
Coupling constants (J) are reported in hertz, and chemical shifts are
reported in parts per million relative to CDCl3 (7.26 ppm for 1H and
77.0 ppm for 13C). Mass spectra were recorded at 70 eV with Fison's VG
Pro spectrometer. High-resolution mass spectra were performed with a
VG Prospec mass spectrometer and with a Micromass Q-TOF-2™.
4.2. (3R,5S,8R,9S,10S,13S,14S)-3-azido-10,13-dimethylhexadecahydro-
17H-cyclopenta[a]phenanthren-17-one (5)
To a solution of PPh3 (4.33 g, 16.5 mmol, 1.1 equiv) in THF (90 mL)
was added diethyl azodicarboxylate (3.54 mL, 18.0 mmol, 1.2 equiv) at
0 °C and the solution was stirred for 10 min. To this solution epian-
drosterone (4.36 g, 15 mmol, 1 equiv) was added. After stirring for an
additional 10 min, diphenylphosphoryl azide (3.87 mL, 18.0 mmol, 1.2
equiv) was added slowly. The reaction mixture was allowed to warm to
room temperature. After 10 h, 0.1 M NaOH was added and the resulting
mixture extracted with 5 × 50 mL DCM. The combined organic layers
were dried over MgSO4, evaporated and the compound was purified by
flash chromatography (SiO2, 30% EtOAc in heptane) to afford the
product in 73% yield. 1H NMR (400 MHz, CDCl3) δ 4.05–3.67 (m, 1H),
2.56–2.33 (m, 1H), 2.14–2.00 (m, 1H), 1.98–1.88 (m, 1H), 1.84–1.62
(m, 5H), 1.59–1.38 (m, 6H), 1.33–1.16 (m, 6H), 1.02 (qd, J = 12.4,
4.8 Hz, 1H), 0.89–0.74 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 58.04,
54.25, 51.45, 47.77, 40.04, 36.06, 35.82, 35.02, 32.82, 32.51, 31.53,
30.72, 27.99, 25.59, 21.73, 20.04, 13.82, 11.57.
4.3. (3R,5S,8R,9S,10S,13S,14S)-3-(dimethylamino)-10,13-
dimethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-one (6)
A solution of azido steroid 5 (2.16 g, 6 mmol, 1 equiv) in a mixture
of THF (6 mL) and aqueous NaOH (1.0 M, 3 mL) was degassed by
purging for 20 min with a slow stream of argon gas through a 20-gauge
stainless steel needle. To the degassed solution was added a solution of
trimethylphosphine in THF (1.0 M, 18 mL, 18 mmol, 3 equiv). After 2 h,
MeOH (90 mL) was added, followed by aqueous HCl (4.0 M, 5 mL), and
then acetic acid (6.86 mL, 120 mmol, 20 equiv). To the resulting so-
lution were added sequentially formalin (37%wt, 11.05 mL, 300 mmol,
50 equiv) and a solution of sodium cyanoborohydride (3.77 g, 60 mmol,
10 equiv) in MeOH (1 mL). After 1 h, the reaction mixture was con-
centrated to remove the bulk of the solvent. The concentrate was par-
titioned between aqueous NaOH (1.0 M, 20 mL) and DCM (40 mL). The
layers were separated. The aqueous layer was extracted with DCM
(4 × 20 mL). The organic layers were combined, and washed with
saturated aqueous sodium chloride solution (30 mL). The combined
organic layers was dried over sodium sulfate, evaporated and purified
by flash chromatography (SiO2, 10% MeOH in DCM; SiO2 was pre-
treated with 1% Et3N in CHCl2). 1H NMR (400 MHz, CDCl3) δ 2.46–2.34
(m, 1H), 2.20 (s, 6H), 2.09–1.96 (m, 2H), 1.95–1.69 (m, 4H), 1.67–1.14
(m, 14H), 1.10–0.95 (m, 1H), 0.94–0.85 (m, 1H), 0.83 (s, 3H), 0.81 (s,
3H). 13C NMR (101 MHz, CDCl3) δ 221.50, 61.72, 54.43, 51.67, 47.97,
43.97, 39.67, 36.42, 35.95, 35.20, 33.12, 31.90, 31.72, 30.90, 28.56,




Dimethylamino steroid 6 (2.22 g, 7.0 mmol) and N-phenylbis(tri-
fluoromethanesulfonimide) (3.75 g, 10.5 mmol) were dissolved in dry
THF (70 mL) and cooled to −78 °C. NaHMDS (14 mL 1.0 M in THF,
14 mmol), was added dropwise at −78 °C and the resulting mixture
was stirred at −78 °C for 10 h. Then the reaction was brought to room
temperature and quenched by addition of saturated aqueous NH4Cl
(20 mL). The mixture was extracted with CH2Cl2 (4 × 30 mL); the
combined organic extracts were washed with water and brine, dried
(MgSO4) and concentrated in vacuo. The residue was purified by flash
chromatography (SiO2, 2% MeOH in DCM; SiO2 was pretreated with
1% Et3N in CHCl2).) to afford the product in 85% yield. 1H NMR
(400 MHz, CDCl3) δ 5.54 (dd, J = 3.3, 1.7 Hz, 1H), 2.29–2.11 (m, 7H),
2.03 (s, 1H), 2.00–1.90 (m, 1H), 1.87–1.78 (m, 1H), 1.75–1.43 (m, 8H),
1.42–1.16 (m, 7H), 1.08–0.91 (m, 5H), 0.84 (s, 3H). 13C NMR
(101 MHz, CDCl3) δ 159.39, 118.57 (q, J = 320.42 Hz), 114.28, 99.99,
77.34, 77.22, 77.02, 76.70, 61.63, 54.54, 54.32, 44.92, 43.85, 39.71,
36.38, 33.92, 33.49, 32.74, 32.72, 31.71, 30.70, 28.53, 28.41, 24.79,
20.11, 20.09, 15.30, 12.09, 12.03, 0.09.
4.5. General procedure for the Suzuki cross-coupling (8–17)
The dimethylamino steroid triflate (0.2 mmol, 1 equiv.), cesium
carbonate (2 equiv.) and the boronic acid (1.05 equiv.) were placed in a
50 mL round-bottomed flask under an argon atmosphere and dissolved
in a 1:1 mixture of water and THF. Pd(PPh3)4 (5%mol) was added and
the reaction mixture was stirred at room temperature (18–22 h.). Upon
completion the reaction mixture was poured into brine (15 mL) and
extracted with ethyl acetate (4 × 5 mL). The combined organic extracts
were dried (MgSO4) and the solvent evaporated in vacuo. The residue
was purified by flash chromatography (silica gel, 10% MeOH in DCM;




The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (63 mg, 83%). 1H
NMR (400 MHz, CDCl3) δ 8.58 (d, J= 2.5 Hz, 1H), 8.42 (d, J= 6.3 Hz,
1H), 7.70–7.53 (m, 1H), 7.22–7.11 (m, 1H), 5.94 (dd, J = 3.3, 1.8 Hz,
1H), 2.43 (s, 6H), 2.26–2.08 (m, 1H), 2.05–1.82 (m, 3H), 1.75–1.66 (m,
2H), 1.66–1.54 (m, 5H), 1.52–1.33 (m, 5H), 1.29–1.01 (m, 5H), 0.98 (s,
3H), 0.86 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 151.91, 148.00,
147.83, 133.87, 133.23, 129.33, 123.10, 62.66, 57.41, 54.02, 47.71,
43.56, 39.58, 36.37, 35.38, 34.15, 32.63, 31.78, 31.60, 31.03, 28.64,
24.26, 20.88, 16.84, 12.17. HRMS (EI): Exact mass calculated for




The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (57 mg, 69%). 1H
NMR (400 MHz, CDCl3) δ 8.47 (d, J= 1.9 Hz, 1H), 8.40 (d, J= 2.4 Hz,
1H), 7.61 (t, J = 2.1 Hz, 1H), 6.12–5.87 (m, 1H), 2.91 (s, 1H), 2.78 (s,
6H), 2.33–2.15 (m, 1H), 2.10–1.91 (m, 3H), 1.85–1.77 (m, 1H),
1.77–1.69 (m, 1H), 1.68–1.58 (m, 6H), 1.57–1.48 (m, 2H), 1.45–1.40
Table 2
EC50 (µM) values of the indicated CDK8 inhibitors on MOLM-13, OCI-AML3,
MV4-11, NRK and H9c2 cells after 48 h of incubation with the compounds. The
data are based on regression analyses from three experiments. For H9c2, the
range for EC50 is given, since cells produced data that did not fit to Eq. (1) given
in the methods section.
Compound MOLM-13 OCI-AML3 MV4-11 NRK H9c2
8 10.2 10.0 10.1 29.7 25–50
9 11.2 7.5 8.6 20.5 12.5–25
12 5.9 4.8 5.4 16.2 12.5–25
13 3.9 2.7 4.1 7.1 6.5–12.5
14 9.0 7.6 5.5 11.4 12.5–25
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(m, 2H), 1.32–1.21 (m, 2H), 1.21–1.05 (m, 2H), 0.98 (s, 3H), 0.88 (s,
3H). 13C NMR (101 MHz, CDCl3) δ 150.52, 146.63, 145.74, 134.35,
133.49, 131.70, 130.98, 64.26, 57.05, 53.30, 47.68, 43.19, 39.24,
36.21, 35.09, 33.97, 31.81, 31.16, 29.81, 28.33, 23.27, 20.81, 16.88,





The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (85 mg, 64%). 1H
NMR (400 MHz, CDCl3) δ 8.47 (d, J= 5.2 Hz, 1H), 7.23 (d, J= 6.1 Hz,
2H), 6.12 (dd, J = 3.4, 1.8 Hz, 1H), 2.36 (s, 6H), 2.27–2.18 (m, 2H),
2.07–1.95 (m, 2H), 1.91–1.82 (m, 1H), 1.77–1.51 (m, 8H), 1.40 (d,
J = 8.6 Hz, 5H), 1.30–1.20 (m, 3H), 1.15–1.07 (m, 1H), 1.01 (s, 3H),
0.86 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 152.60, 149.59, 144.67,
131.43, 121.17, 62.24, 57.37, 54.04, 47.39, 43.58, 39.52, 36.27, 35.18,
33.94, 32.61, 31.68, 31.52, 31.21, 28.54, 24.39, 20.73, 16.76, 12.05.





The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (62 mg, 72%). 1H
NMR (400 MHz, CDCl3) δ 9.13 (s, 1H), 8.29 (s, 1H), 7.96 (dd, J = 25.9,
8.1 Hz, 2H), 7.73–7.52 (m, 2H), 5.80 (s, 1H), 2.56 (s, 6H), 2.37 (d,
J = 14.4 Hz, 1H), 2.14 (t, J = 13.2 Hz, 1H), 1.83 (dd, J = 23.8,
13.2 Hz, 4H), 1.53 (s, 6H), 1.45–1.32 (m, 2H), 1.25 (dd, J = 14.2,
7.3 Hz, 7H), 0.95 (s, 3H), 0.85 (s, 4H). 13C NMR (101 MHz, CDCl3) δ
151.20, 149.80, 141.64, 135.54, 131.57, 129.99, 129.37, 128.38,
127.46, 126.91, 125.69, 62.99, 58.19, 56.98, 53.80, 49.75, 43.18,
39.28, 36.25, 34.80, 34.45, 32.26, 32.23, 31.50, 30.42, 28.47, 23.71,





The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (60 mg, 70%). 1H
NMR (400 MHz, CDCl3) δ 9.19 (s, 1H), 8.47 (d, J = 6.0 Hz, 1H),
7.94–7.79 (m, 2H), 7.59–7.52 (m, 1H), 7.45 (dd, J = 7.2, 1.2 Hz, 1H),
5.80–5.67 (m, 1H), 2.58 (s, 6H), 2.41–2.30 (m, 1H), 2.21–2.08 (m, 1H),
1.97–1.74 (m, 4H), 1.71–1.15 (m, 15H), 0.92 (s, 3H), 0.85 (s, 3H). 13C
NMR (101 MHz, CDCl3) δ 152.49, 151.17, 142.88, 135.42, 135.15,
130.72, 129.51, 128.95, 126.38, 126.27, 119.33, 63.10, 56.98, 53.74,
49.69, 43.15, 39.27, 36.25, 34.91, 34.41, 32.22, 32.15, 31.46, 30.34,
28.46, 23.64, 20.72, 16.48, 12.01. HRMS (EI): Exact mass calculated for




The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (68 mg, 79%). 1H
NMR (400 MHz, CDCl3) δ 9.16 (s, 1H), 8.46 (d, J = 5.9 Hz, 1H), 7.85
(d, J = 8.6 Hz, 1H), 7.73 (d, J = 1.7 Hz, 1H), 7.67–7.56 (m, 2H), 6.10
(dd, J = 3.2, 1.7 Hz, 1H), 2.74 (s, 1H), 2.64 (s, 6H), 2.31–2.19 (m, 1H),
2.15–1.86 (m, 3H), 1.79–1.32 (m, 13H), 1.31–1.21 (m, 2H), 1.07 (s,
4H), 0.87 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 154.06, 151.89,
142.96, 139.43, 135.95, 130.40, 127.55, 127.24, 127.22, 122.85,
120.69, 63.43, 57.27, 53.55, 47.62, 43.13, 39.30, 36.11, 35.33, 33.90,
31.99, 31.71, 31.25, 30.06, 28.31, 23.43, 20.77, 16.85, 11.95. HRMS





The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (65 mg, 76%). 1H
NMR (400 MHz, CDCl3) δ 9.19 (s, 1H), 8.44 (d, J = 5.7 Hz, 1H), 7.87
(d, J = 1.5 Hz, 1H), 7.72 (d, J = 1.2 Hz, 2H), 7.58 (d, J = 5.6 Hz, 1H),
6.05 (dd, J = 3.3, 1.7 Hz, 1H), 2.96 (s, 1H), 2.77 (s, 6H), 2.30–2.17 (m,
1H), 2.14–2.07 (m, 1H), 2.06–1.92 (m, 2H), 1.84–1.69 (m, 2H),
1.69–1.56 (m, 7H), 1.47–1.34 (m, 3H), 1.31–1.21 (m, 3H), 1.25–1.13
(m, 1H), 1.07 (s, 3H), 0.88 (s, 3H). 13C NMR (101 MHz, CDCl3) δ
153.90, 152.54, 142.53, 136.36, 134.69, 130.32, 129.23, 128.78,
126.13, 123.90, 120.18, 63.98, 57.15, 53.30, 47.57, 42.94, 39.19,
36.08, 35.31, 33.88, 31.72, 31.59, 31.11, 29.63, 28.22, 23.08, 20.77,





The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (59 mg, 71%). 1H
NMR (400 MHz, CDCl3) δ 8.58–8.17 (m, 1H), 7.27 (d, J = 7.9 Hz, 1H),
7.16 (t, J = 2.8 Hz, 1H), 7.12 (t, J = 7.7 Hz, 1H), 7.04–6.98 (m, 1H),
6.64 (t, J = 2.9 Hz, 1H), 5.99 (dd, J = 3.2, 1.7 Hz, 1H), 2.39 (s, 6H),
2.34–2.26 (m, 2H), 2.13–2.02 (m, 1H), 1.92–1.80 (m, 2H), 1.79–1.72
(m, 1H), 1.69–1.22 (m, 14H), 1.19–1.08 (m, 1H), 1.03 (s, 3H), 0.86 (s,
3H). 13C NMR (101 MHz, CDCl3) δ 153.57, 136.04, 130.26, 128.48,
127.33, 123.75, 121.34, 118.12, 109.66, 103.01, 62.51, 57.25, 54.26,
48.64, 43.52, 39.65, 36.29, 35.48, 34.23, 32.57, 31.94, 31.69, 31.04,
28.64, 24.21, 20.84, 17.01, 12.07. HRMS (EI): Exact mass calculated for




The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (55 mg, 66%). 1H
NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 7.69–7.60 (m, 1H), 7.32–7.27
(m, 1H), 7.25–7.22 (m, 1H), 7.15 (dd, J = 3.2, 2.3 Hz, 1H), 6.57–6.48
(m, 1H), 5.88–5.74 (m, 1H), 2.29 (s, 6H), 2.24–2.15 (m, 1H), 2.13–2.05
(m, 2H), 2.03–1.93 (m, 1H), 1.89–1.80 (m, 1H), 1.76–1.68 (m, 1H),
1.69–1.50 (m, 6H), 1.46–1.32 (m, 5H), 1.28–1.20 (m, 2H), 1.14–1.07
(m, 1H), 1.05 (s, 3H), 0.95 (dd, J = 11.9, 10.0 Hz, 1H), 0.88 (s, 3H).
13C NMR (101 MHz, CDCl3) δ 156.04, 135.09, 129.47, 127.90, 125.35,
124.48, 121.87, 118.66, 110.71, 102.86, 62.05, 57.76, 54.54, 47.71,
43.93, 39.90, 36.46, 35.86, 34.29, 32.99, 31.89, 31.83, 31.58, 28.89,
24.91, 21.01, 16.97, 12.24. HRMS (EI): Exact mass calculated for




The compound was prepared following the general procedure de-
scribed. The product was isolated as colorless solid (53 mg, 64%). 1H
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NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 7.54 (d, J = 8.2 Hz, 1H),
7.43–7.36 (m, 1H), 7.22–7.09 (m, 2H), 6.63–6.36 (m, 1H), 5.87 (dd,
J = 3.2, 1.7 Hz, 1H), 2.31 (s, 6H), 2.24–2.17 (m, 1H), 2.16–2.13 (m,
1H), 2.12–2.07 (m, 1H), 2.04–1.93 (m, 1H), 1.90–1.81 (m, 1H),
1.77–1.70 (m, 1H), 1.68–1.50 (m, 6H), 1.48–1.33 (m, 5H), 1.29–1.21
(m, 2H), 1.17–1.08 (m, 1H), 1.05 (s, 3H), 1.02–0.95 (m, 1H), 0.88 (s,
3H). 13C NMR (101 MHz, CDCl3) δ 155.77, 135.97, 131.57, 126.73,
125.94, 124.30, 120.06, 119.62, 108.99, 102.41, 62.04, 57.65, 54.39,
47.62, 43.74, 39.75, 36.34, 35.77, 34.16, 32.82, 31.73, 31.55, 31.49,
28.72, 24.66, 20.91, 16.91, 12.11. HRMS (EI): Exact mass calculated for
C29H40N2 [M+H]+: 417.3225, found 417.3264.
4.16. Protein kinase assay
For the CDK8 and CDK11 profiling we used a kinase selectivity and
profiling assay (DiscoveRx).39 The assay uses kinase-tagged T7 phage
strains which were grown in parallel in 24-well blocks in an E. coli host
derived from the BL21 strain. E. coli were grown to log-phase and in-
fected with T7 phage from a frozen stock (multiplicity of infec-
tion = 0.4) and incubated with shaking at 32 °C until lysis
(90–150 min). The lysates were centrifuged (6000g) and filtered
(0.2 μm) to remove cell debris. Streptavidin-coated magnetic beads
were treated with biotinylated small molecule ligands for 30 min at
room temperature to generate affinity resins for kinase assays. The li-
ganded beads were blocked with excess biotin and washed with
blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM
DTT) to remove unbound ligand and to reduce non-specific phage
binding. Binding reactions were assembled by combining kinases, li-
ganded affinity beads, and test compounds in 1x binding buffer (20%
SeaBlock, 0.17x PBS, 0.05% Tween 20, 6 mM DTT). Test compounds
were prepared as 40x stocks in 100% DMSO and directly diluted into
the assay. All reactions were performed in polypropylene 384-well
plates in a final volume of 20 µL. The assay plates were incubated at
room temperature with shaking for 1 h and the affinity beads were
washed with wash buffer (1x PBS, 0.05% Tween 20). The beads were
then re-suspended in elution buffer (1x PBS, 0.05% Tween 20, 0.5 μM
non-biotinylated affinity ligand) and incubated at room temperature
with shaking for 30 min. The kinase concentration in the eluates was
measured by qPCR. The test compounds were screened at 50 nM, and
results for primary screen binding interactions are reported as POC
(percent of control). The negative control consists of adding an equal
DMSO volume without a test compound and the positive control consist
of a control compound. From this POC is calculated: ((test compound
signal − positive control signal)/(negative control signal − positive
control signal)) × 100%. Negative control = DMSO (100% Ctrl); Po-
sitive control = control compound (0% Ctrl), where lower numbers
indicate stronger hits in the matrix.
For the binding constant (Kd) determination an 11-point 3-fold se-
rial dilution of each test compound was prepared in 100% DMSO at
100x final test concentration and subsequently diluted to 1x in the
assay (final DMSO concentration = 1%). Most Kd values were de-
termined using a compound top concentration = 30,000 nM. The Kd
values were calculated with a standard dose-response curve using the
Hill equation and are expressed as an average of two determinations.
4.17. Cell growth inhibition (cytotoxicity)
All cell culturing media and serum were from Sigma-Aldrich (St.
Louis, MO, USA). The human acute myeloid leukemia (AML) cell lines
MOLM-13 (ACC: 554,40) and OCI-AML3 (ATCC, ACC-528) were cul-
tured in RPMI medium (R5886) enriched with 10% fetal bovine serum
(F7524) and 2 mM L-glutamine (G7513). The human AML cell line
MV4-11 (ATCC, CRL-9591) was cultured in Iscove medium (I3390)
enriched with 10% fetal bovine serum (F7524) and 8 mM L-glutamine
(G7513). The normal rat kidney epithelial (NRK, ATCC, CRL-6509) and
the rat cardiomyoblast (H9c2, ATCC, CRL-1446) cells were cultured in
DMEM medium (D6429) enriched with 10% fetal bovine serum
(F7524). All cell lines were additionally supplemented with 100 IU/mL
penicillin and 100 µg/mL streptomycin (P0781). The cells were cul-
tured in a humidified atmosphere under 20% O2 at 37 °C.
All analogs were dissolved in DMSO (D5879, Sigma-Aldrich) to a
stock concentration of 25 mM before testing, and stored at −80 °C. For
cytotoxic testing, the three AML cell lines were seeded at 10,000 cells/
well, while NRK cells were seeded as 2000 cells/well and H9c2 as 2500
cells/well in 96-well Microplates (#167008, Thermo Scientific™ Nunc™
MicroWell™) with 0.1 mL medium/well. The cells were exposed to
various concentrations of CDK8 inhibitors for 48 h before the cell
proliferation reagent WST-1 (11644807001, Roche Diagnostics, Sigma-
Aldrich) was used to assess the viability, in accordance with the man-
ufacturer’s instructions. The cells were next fixed in 2% buffered for-
maldehyde (pH 7.4) with the DNA-specific dye Hoechst 33,342
(Polysciences Inc.) and assessed for cell death by UV-microscopy based
on nuclear morphology. Viability assessment with these two methods is
shown to correlate well with cells exposed to kinase inhibitors37.
EC50 values were determined based on data from WST-1 assay in
combination with microscopic evaluation of cell death, using four-
parameter regression analysis function in the SigmaPlot software
(Systat Software inc. San Jose, CA):
= +
+ ( )




where Y is the response (WST-1 signal or percent apoptosis), min and
max are minimum and maximum response, X is concentration of
analog, EC50 equals the point of inflection, i.e. the point that gives half
of maximum response, and h is the Hill’s slope of the curve.
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